⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
globenewswire.com
TNXP
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
TNXP